Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Umbilical cord blood stem… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Umbilical cord blood stem cell therapy in premature brain injury: Opportunities and challenges

Forskningsöversiktsartikel
Författare X. R. Peng
J. Song
B. B. Li
C. L. Zhu
X. Y. Wang
Publicerad i Journal of Neuroscience Research
Sidor 11
ISSN 0360-4012
Publiceringsår 2019
Publicerad vid Institutionen för neurovetenskap och fysiologi
Sidor 11
Språk en
Länkar dx.doi.org/10.1002/jnr.24548
Ämnesord brain injury, cerebral palsy, preterm birth, stem cell, stem cell, transplantation, umbilical cord blood, white matter injury, recombinant-human-erythropoietin, extremely preterm infants, white-matter injury, cerebral-palsy, neurodevelopmental outcomes, intraventricular hemorrhage, transplantation, children, infusion, feasibility, Neurosciences & Neurology
Ämneskategorier Neurovetenskaper

Sammanfattning

Preterm birth and associated brain injury are the primary cause of cerebral palsy and developmental disabilities and are among the most serious global health issues that modern society faces. Current therapy for infants suffering from premature brain injury is still mainly supportive, and there are no effective treatments. Thus there is a pressing need for comparative and translational studies on how to reduce brain injury and to increase regeneration and brain repair in preterm infants. There is strong supporting evidence for the use of umbilical cord blood (UCB)-derived stem cell therapy for treating preterm brain injury and neurological sequelae. UCB-derived stem cell therapy is effective in many animal models and has been shown to be feasible in clinical trials. Most of these therapies are still experimental, however. In this review, we focus on recent advances on the efficacy of UCB-derived stem cell therapy in preterm infants with brain injury, and discuss the potential mechanisms behind their therapeutic effects as well as application strategies for future preclinical and clinical trials.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?